Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)
Part of paid clinical trials in Goodyear, Arizona.
- Sponsor
- Amgen
- Study ID
- NCT07531095
- Phase
- PHASE1
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 99 Years
- Healthy Volunteers
- Not accepted
Interventions
- ZL-1310 — DRUGZL-1310 will be administered as an IV infusion.
- Tarlatamab — DRUGTarlatamab will be administered as an IV infusion.
- Durvalumab — DRUGDurvalumab will be administered as an IV infusion.
Study Details
The primary objective of this trial is to evaluate the safety and tolerability of tarlatamab in combination with ZL-1310 with or without durvalumab and to determine the maximum tolerated combination dose (MTCD) and/or recommended phase 2 dose (RP2D) of ZL-1310 in combination with tarlatamab.
Key Dates
- First listed
- Apr 15, 2026
- Start date
- Apr 21, 2026
- Status verified
- Aug 2026
- Primary completion
- May 21, 2028
- Completion
- May 21, 2031
Study Design
- Enrollment
- 160 participants (estimated)
- Allocation
- NON_RANDOMIZED
- Intervention model
- SEQUENTIAL
- Primary purpose
- TREATMENT
Arms
- Experimental: Dose Exploration (Part 1)Multiple dose levels of ZL-1310 will be explored in combination with tarlatamab administered intravenously (IV).
- Experimental: Dose Expansion (Part 2)ZL-1310 will be administered IV at the selected maximum tolerated combination dose (MTCD) or recommended phase 2 dose (RP2D) in combination with tarlatamab administered IV.
- Experimental: Triplet Combination (Part 3)ZL-1310 will be administered at MTCD or RP2D in combination with tarlatamab and an anti-PD-L1 (durvalumab) each administered IV.
Primary Outcome Measure
Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs) [ Time Frame: Up to 3.5 years ]
Central Contacts
- Amgen Call Center866-572-6436
Locations (7)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| City of Hope Cancer Center Phoenix | Goodyear | Arizona | 85338 | - |
| Moffitt Cancer Center | Tampa | Florida | 33612 | - |
| City of Hope Chicago | Zion | Illinois | 60099 | - |
| Health Partners Cancer Center at Regions Hospital | Saint Paul | Minnesota | 55101 | - |
| New York University Cancer Institute | New York | New York | 10016 | - |
| Baptist Cancer Center | Memphis | Tennessee | 38120 | - |
| Next Virginia | Fairfax | Virginia | 22031 | - |
Find similar trials in Goodyear, AZ
By condition
By specialty
Related Studies
- PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56PHASE1/PHASE2 · Recruiting · Memorial Sloan Kettering Cancer Center · New York, New York
- The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)PHASE1/PHASE2 · Recruiting · PMV Pharmaceuticals, Inc · La Jolla, California
- Tempus Small Cell Lung Cancer Observational Study (Sculptor)Recruiting · Tempus AI · Aurora, Colorado
- Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More TreatmentPHASE2 · Recruiting · Advenchen Pharmaceuticals, LLC. · Birmingham, Alabama